krro-110 - Search News

Korro Bio gets Orphan Drug Designation from FDA for its genetic disorder treatment

Korro Bio (NASDAQ:KRRO) said on Friday that it received U.S. FDA's orphan drug designation for investigational medicine KRRO-110 to treat alpha-1 antitrypsin deficiency. Stock is up about 10% premarket.

MarketWatch · 2d

Korro Bio's KRRO-110 Gets FDA Orphan Drug Designation

Korro Bio disclosed that the Food and Drug Administration granted orphan drug designation to its potential genetic disorder drug KRRO-110. Shares rose 17.6% to $29 in premarket trading. The stock is down about 60% over the last year.

Markets Insider · 2d

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

KRRO-110 is the first RNA editing development candidate from Korro’s proprietary OPERA TM platform and is currently being evaluated in the Phase 1/2a REWRITE clinical study for AATD. Dosing of the first two single ascending dose cohorts in healthy adult volunteers has been completed, and an interim readout is expected in the second half of 2025.

Hosted on MSN28d

Korro secures approvals in Australia to commence AATD trial of KRRO-110

Korro Bio has secured approvals in Australia to commence the two-part Phase I/IIa REWRITE trial of its investigational product, KRRO-110, aimed at treating alpha-1 antitrypsin deficiency (AATD).

Korro Bio receives ODD from U.S. FDA for AATD

Korro Bio (KRRO) announced that the U.S. Food and Drug Administration has granted orphan drug designation, ODD, to the investigational medicine ...

Investing2d

FDA grants orphan drug status to Korro’s AATD treatment

Korro’s Chief Medical Officer, Kemi Olugemo, MD, emphasized the importance of developing new treatments for AATD, noting the potential of KRRO-110 to treat liver and lung manifestations of the ...

Yahoo Finance9d

Korro Bio, Inc. (KRRO)

Todd Chappell, Chief KRRO-110 is the first product candidate from Korro’s proprietary RNA editing OPERATM platformInterim readout from REWRITE expected in the second half of 2025 Korro to ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results